Lifileucel
- Generic Name
- Lifileucel
- Drug Type
- Biotech
- CAS Number
- 2306267-74-1
- Unique Ingredient Identifier
- R0835E18NH
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Phase 2
Recruiting
- Conditions
- Squamous Cell Carcinoma of the Head and NeckMetastatic MelanomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 245
- Registration Number
- NCT03645928
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
🇬🇧The Royal Marsden NHS Foundation Trust, London, England, United Kingdom
🇺🇸University of Southern California, Los Angeles, California, United States
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT02360579
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇬🇧Royal Marsden NHS Trust, London, England, United Kingdom
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath